Keros Therapeutics, Inc.

The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing novel protein therapeutics for disorders linked to dysfunctional transforming growth factor-beta (TGF-ß) signaling pathways. Its pipeline centers on engineered ligand traps designed to target tissues such as skeletal muscle, bone, adipose tissue, and blood. The primary product candidate, rinvatercept, targets neuromuscular conditions including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its other key candidate, elritercept, addresses cytopenias such as anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. The company aims to serve patient populations suffering from rare neuromuscular and hematological disorders.

Operating as a development-stage biopharmaceutical enterprise, the company conducts preclinical studies and clinical trials, including global collaborative partnerships. It has established an exclusive licensing agreement covering the worldwide development, manufacturing, and commercialization of elritercept outside of mainland China, Hong Kong, and Macau. The provided excerpt does not disclose the company's specific headquarters location or physical facility count.

Summary of the business section of Keros Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 78 full-time employees, including 27 who hold Ph.D.”